Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma

IMPORTANCE: Axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy, represents a new and potentially curative treatment option for B-cell lymphoma. It is expected to have long-term survival benefits; however, long-term survival data are limited. OBJECTIVE: To estimate the long-term surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Whittington, Melanie D., McQueen, R. Brett, Ollendorf, Daniel A., Kumar, Varun M., Chapman, Richard H., Tice, Jeffrey A., Pearson, Steven D., Campbell, Jonathan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484589/
https://www.ncbi.nlm.nih.gov/pubmed/30794298
http://dx.doi.org/10.1001/jamanetworkopen.2019.0035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484589/
https://www.ncbi.nlm.nih.gov/pubmed/30794298
http://dx.doi.org/10.1001/jamanetworkopen.2019.0035

Ejemplares similares